Homologous recombination-deficient high-grade serous ovarian cancers exhibit distinct morphological features

Read full text
Authors: Kattreen Hanna, Gabriel Levin, Miryam Al Nasir, Roxanne Lacouline-Boulanger, Lawrie Shahbazian, Sarah-Slim Diwan, Joyce Li, Denia Hamidi, Lea Stephan, Mina Hmimas, Nicole Zhang, Phuong-Nam Nathalie Nguyen
+11 more Lara Richer, Karine Jacob, Andrea Gomez, Reitan Ribeiro, Victoria Mandilaras, Laurence Bernard, Xing Ziggy Zeng, Robert A. Soslo, L. Gilbert, Shuk On Annie Leung, Basile Tessier-Cloutier
Cited by: 1
References: 18

Abstract

OBJECTIVE: Access to homologous recombination testing remains limited in many centers. We aim to correlate the morphology and immunophenotype of high-grade serous ovarian carcinoma with homologous recombination statuses. METHODS: A retrospective analysis of a high-grade serous ovarian carcinoma tumors with known homologous recombination status. A pathological review of morphology was performed for each tumor, along with immunohistochemical profiling. Tumor morphology was classified as (1) solid, pseudo-endometrioid, or transitional (2) micropapillary or nested. RESULTS: Overall, 81 tumors were included. The median age was 62 (interquartile range; 52-71). Of those, 27 (33.3%) tumors were BRCA1mut, 19 (23.5%) were BRCA2mut, 15 (18.5%) tumors had no BRCA1 or BRCA2 mutations but exhibited a genomic instability score ≥42 and were classified as BRCA1/2-wild-type with homologous recombinant deficient. The remainder 20 (24.7%) cases were homologous recombinant proficient. The proportion of tumors with solid transitional-like morphology was higher in BRCA1 (12/21, 57%) and BRCA2 (12/18, 67%) compared to the tumors with homologous recombinant proficient (3/17, 18%), p =.019. When stratified by genomic instability score, tumors with low score (genomic instability score 26), p =.03. PAX8 diffuse expression was detected in 71% of BRCA1, 65% of BRCA2, 92% of BRCA-wild-type homologous recombinant deficient tumors, and 100% of homologous recombinant proficient tumors, p =.071. The proportion of diffuse expression was higher in homologous recombinant proficient (100%) versus BRCA2 (65%) (Bonferroni-adjusted pairwise comparisons). CONCLUSIONS: Homologous recombinant deficient tumors are associated with the solid transitional-like morphology, with the BRCA1/2-mutated homologous recombinant deficient cases showing the strongest correlation. Genomic instability score alone may not fully capture the spectrum of homologous recombinant deficient-related phenotypes. The variation in solid transitional-like morphology features among BRCA1- or BRCA2-mutated, BRCA1/2- wild-type with homologous recombinant deficient, and homologous recombinant proficient cases may reflect the diverse biological spectrum of different homologous recombination alterations.

Fields of Study & Subjects

PARP inhibition in cancer therapy Ovarian cancer diagnosis and treatment DNA Repair Mechanisms

Publication details

Journal / source
International Journal of Gynecological Cancer
Publisher
Elsevier BV
Volume
36
Issue
9
Pages
104690–104690
Publication date
9 April 2026
Language
EN